Questions about COVID-19?

What Patients & Families Need to Know | New Visitor Policy | Guidance for Community Healthcare Providers

A photo of John Perentesis.

Director, Division of Oncology

Institute Co-Director, Cancer and Blood Diseases Institute

Deb Kleisinger Endowed Chair

Professor, UC Department of Pediatrics

513-636-8241

513-636-3549

Board Certified

Best Doctors logo

My Biography & Research

Biography

John P. Perentesis, MD, FAAP, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells. His laboratory is also using tumor patients genomics research for personalizing therapies. In national efforts for new anticancer drug development, he serves in key roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest children's cancer research entity.

In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national COG Executive Committee. He also serves as vice-chair for the COG Adolescent & Young Adult Cancer Steering Committee and as a member of the Hematology/Oncology and Institutional Performance Monitoring Steering Committees.

Dr. Perentesis has been elected by his peers for inclusion in the Best Doctors in America List since 1998.

Clinical Interests

Young adult cancers; acute myeloid & lymphoid leukemia; Hodgkin lymphoma; new anticancer therapy development

Research Interests

Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Leukemia, Sarcoma, Cancer and Blood Diseases, Young Adult Cancer, Oncology, Cancer and Blood Diseases

Cincinnati Children's Blog

Proton Therapy

BlogCancer and Blood Diseases

Proton Therapy: A Game Changer in Cancer Treatment

By John Perentesis, MD8/6/2016

Still Jersey Money

BlogCancer and Blood Diseases

Still Jersey Money: We’ll Make Science Count for Kids with Cancer

By John Perentesis, MD11/7/2014

My Locations

My Education

MD: University of Michigan, Ann Arbor, MI, 1980.

Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.

Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.

Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.

Certification: Pediatrics, 1989; Hematology/Oncology, 1990.

My Publications

Selected Publication

Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Anderson, CP; Matthay, KK; Perentesis, JP; Neglia, JP; Bailey, HH; Villablanca, JG; Groshen, S; Hasenauer, B; Maris, JM; Seeger, RC; et al. Pediatric Blood and Cancer. 2015; 62:1739-1746.

The signaling axis atypical protein kinase C lambda/iota-Satb2 mediates leukemic transformation of B-cell progenitors. Nayak, RC; Hegde, S; Althoff, MJ; Wellendorf, AM; Mohmoud, F; Perentesis, J; Reina-Campos, M; Reynaud, D; Zheng, Y; Diaz-Meco, MT; et al. Nature Communications. 2019; 10.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al. Science Translational Medicine. 2019; 11:eaaw8828-eaaw8828.

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Widemann, BC; Lu, Y; Reinke, D; Okuno, SH; Meyer, CF; Cote, GM; Chugh, R; Milhem, MM; Hirbe, AC; Kim, A; et al. Sarcoma. 2019; 2019:1-8.

Improved chemotherapy modeling with RAG-based immune deficient mice. Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O’Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. PLoS ONE. 2019; 14:e0225532-e0225532.

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. Meyer, SE; Muench, DE; Rogers, AM; Newkold, TJ; Orr, E; O'Brien, E; Perentesis, JP; Doench, JG; Lal, A; Morris, PJ; et al. The Journal of Experimental Medicine. 2018; 215:2115-2136.

KLF5 controls glutathione metabolism to suppress p190-BCRABL+ B-cell lymphoblastic leukemia. Zhang, C; D'Alessandro, A; Wellendorf, AM; Mohmoud, F; Serrano-Lopez, J; Perentesis, JP; Komurov, K; Alexe, G; Stegmaier, K; Whitsett, JA; et al. Oncotarget. 2018; 9:29665-29679.

Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Weber, DC; Habrand, JL; Hoppe, BS; Kayser, CH; Laack, NN; Langendijk, JA; MacDonald, SM; McGovern, SL; Pater, L; Perentesis, JP; et al. Radiotherapy and Oncology. 2018; 128:44-55.

An Update From the Pediatric Proton Consortium Registry. Hess, CB; Indelicato, DJ; Paulino, AC; Hartsell, WF; Hill-Kayser, CE; Perkins, SM; Mahajan, A; Laack, NN; Ermoian, RP; Chang, AL; et al. Frontiers in Oncology. 2018; 8.

Viral surveillance using PCR during treatment of AML and ALL. Dixon, SB; Lane, A; O'Brien, MM; Burns, KC; Mangino, JL; Breese, EH; Absalon, MJ; Perentesis, JP; Phillips, CL. Pediatric Blood and Cancer. 2018; 65:e26752-e26752.